Roche buys into NASH space with US acquisition

28 November 2018

Swiss pharma giant Roche (ROG: SIX) edged 1.02% higher to 252.15 Swiss francs this morning, after it was revealed it is seeking a position in the hot area of liver disease.

It is acquiring the San Diego, USA-based biotech start-up Jecure Therapeutics, and its novel drug discovery programs targeting serious inflammatory diseases, today announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche Group.

Financial terms of the deal were not disclosed. However, with this acquisition, Roche’s USA-based Genentech unit will obtain full rights to Jecure’s entire preclinical portfolio of NLRP3 inhibitors, being developed for fighting inflammatory diseases like non-alcoholic steatohepatitis (NASH) and liver fibrosis as well as gout, inflammatory bowel disease and cardiovascular diseases

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK